Opiate substitution therapy halves HIV risk for people who inject drugs

Michael Carter
Published: 15 October 2012

Opiate substitution therapy reduces the risk of HIV infection by half for individuals who inject drugs, according to the results of a systematic review and meta-analysis published in the British Medical Journal.

“There is evidence from published and unpublished observational studies that opiate substitution treatment is associated with an average 54% reduction in the risk of new HIV infections among people who inject drugs,” write the investigators. “To our knowledge this is the first study that synthesises the available evidence and generates a quantitative estimate of the impact of opiate substitution treatment on incidence of HIV.”

Injecting drug users are among the groups most affected by HIV. Up to 40% of injecting drugs users in some settings are infected with the virus, and emerging epidemics in parts of Russia, eastern Europe and Asia are largely driven by injecting drug use.

Methadone or buprenorphine are prescribed to people who are dependant on opiates, and both drugs are on the World Health Organization list of essential medicines. In addition to reducing craving for illicit substances, therapy with these drugs has been shown to have other benefits. These include reductions in drug-related mortality, reduced offending and improved adherence to antiretroviral therapy.

There is also some evidence that injecting drug users who are prescribed opiate substitution therapy have a reduced risk of infection with HIV.

An international team of investigators wanted to establish a clearer understanding of the impact of opiate substitution treatment in relation to HIV incidence among injecting drug users.

They therefore conducted a systematic review and meta-analysis of the results of randomised studies, prospective cohort studies, or case-control studies that directly examined the effect of opiate substitution therapy on HIV incidence in injecting drug users.

Studies published up to March 2011 were included in the investigators’ analyses.

A total of 15 studies were identified. All looked at the impact of methadone maintenance therapy. The size of the studies ranged from 80 to 2546 individuals; the duration of follow-up was between one and 20 years; and the research was published between 1992 and 2009.

The authors were able to pool the results of nine studies to assess the impact of opiate substitution treatment in relation to HIV transmission. The results of these studies provided 819 incident HIV infections over 23,607 person-years of follow-up.

Overall, opiate substitution treatment reduced the risk of infection with HIV by 54% (RR = 0.46; 95% CI, 0.32-0.67, p < 0.001).

The authors then restricted their analysis to the six studies that adjusted for confounders. A total of 450 incident infections were reported in these studies over 10,064 person-years of follow-up. Methadone substitution therapy reduced the risk of infection with HIV by 40% (RR = 0.60; 95% CI, 0.42-0.85, p = 0.004).

A significant benefit of opiate substitution therapy on HIV transmission risk continued to be evident when the authors restricted their analysis to the five studies with the lowest risk of bias (RR = 0.61; 95% CI, 0.41-0.91, p = 0.016).

There was no evidence that the benefits of opiate replacement therapy differed by region or were affected by the provision of incentives to people. However, there was a weak association between longer duration of substitution therapy and greater benefit in terms of reduced HIV incidence.

Four studies looked at the impact of methadone detoxification treatment. There were 687 incident HIV infections over 20,616 person-years of follow-up in these studies. The pooled results showed detoxification therapy was associated with an increased risk of infection with HIV when compared to either no treatment or methadone replacement therapy (RR = 1.54; 95% CI, 1.05-2.26, p = 0.026).

“Our findings further support and highlight the importance of opiate substitution treatment in the prevention of HIV among people who inject [opiate] drugs,” comment the investigators. “These data further support studies showing a range of benefits of opiate substitution treatment, and support calls for the global increase of harm reduction interventions to reduce the transmission of HIV between people who inject drugs and between people who inject drugs and the wider community.”


MacArthur GJ et al. Opiate substitution treatment and HIV transmission in people who inject drugs: a systematic review and meta-analysis. BMJ 345: e5945 (doi: 10.1136/bmj.e5945), 2012.

Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.